FPR2 and atrial fibrillation: In vivo, FPR2 antagonism increased AF inducibility and fibrosis, whereas Ac2-26 improved insulin resistance, mitigated atrial lipid accumulation and oxidative stress, normalized RyR2 phosphorylation, and limited structural/electrical remodeling; cardiomyocyte-targeted AMPK knockdown abrogated these benefits [127].